Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

ICHICH guidelineBioequivalenceMedicinesHigh confidenceLast verified October 4, 2026

M13A

Bioequivalence for Immediate-Release Solid Oral Dosage Forms

Current edition

Step 4, 23 July 2024

About this standard

Gives recommendations for bioequivalence studies of immediate-release solid oral dosage forms such as tablets and capsules, during development and after approval. It does not cover how regulators decide based on the results.

Recognition by market

Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts

  • United StatesImplemented
    Edition accepted
    -
    National code
    89 FR 86809

    Effective October 31, 2024

  • European UnionImplemented
    Edition accepted
    -
    National code
    EMA/CHMP/ICH/953493/2022

    Effective January 25, 2025

  • United KingdomImplemented
    Edition accepted
    -
    National code
    -

    Effective January 1, 2025

  • JapanNot yet implemented
    Edition accepted
    -
    National code
    -

    Implementation is in progress.

  • ChinaImplemented
    Edition accepted
    -
    National code
    -

    Effective May 20, 2026

  • CanadaImplemented
    Edition accepted
    -
    National code
    File #: 25-102237-854

    Effective January 12, 2026

  • BrazilNot yet implemented
    Edition accepted
    -
    National code
    -

    Not yet implemented by this regulator.

  • South KoreaNot yet implemented
    Edition accepted
    -
    National code
    -

    Implementation is in progress. Date listed: 31 December 2026.

  • SwitzerlandImplemented
    Edition accepted
    -
    National code
    -

    Effective July 23, 2024. ICH guidelines apply in Switzerland automatically once they reach Step 4.

  • MexicoNot yet implemented
    Edition accepted
    -
    National code
    -

    Not yet implemented by this regulator.

  • Saudi ArabiaImplemented
    Edition accepted
    -
    National code
    -

    Effective April 15, 2026

  • SingaporeNot yet implemented
    Edition accepted
    -
    National code
    -

    Implementation is in progress.

  • TaiwanNot yet implemented
    Edition accepted
    -
    National code
    -

    Implementation is in progress.

Testing requirements that cite it

Open the market page and its pathway pages for the full requirement, protocol and report content

Related standards: JP guideline for bioequivalence studies of generic products, MHRA comparator product guidance, CPMP/EWP/QWP/1401/98 Rev 1, JP BE guideline, formulation changes (oral solid), NMPA Notice 2016 No. 61, Annex 3, FDA BE guidance for ANDAs (PK endpoints), NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9. See all standards.

Not legal or regulatory advice. Check the current official rules before you act. Parts of the approvals data are official open data reused under open licences. Data sources.

LinkedInLinkedInXXYouTubeYouTube